Chemistry:Raludotatug deruxtecan
From HandWiki
 | There do not appear to be enough references currently present in this article to demonstrate notability. However, an editor has performed a search and claims that there are sufficient sources to indicate that this is a notable topic. (May 2025) (Learn how and when to remove this template message) |
Short description: Experimental anti-cancer treatment
| Identifiers | |
|---|---|
| CAS Number | |
| DrugBank | |
| UNII | |
| ChEMBL | |
Raludotatug deruxtecan (DS-6000) is an experimental anti-cancer treatment developed by Daiichi Sankyo and Merck. It is an antibody–drug conjugate that consists of a humanized IgG1 monoclonal antibody against the tumor-associated antigen cadherin-6 (CDH6), conjugated to deruxtecan (DXd), a cytotoxic DNA topoisomerase I inhibitor.[1]
In September, 2025, it received breakthrough therapy designation from the FDA for adult patients with platinum-resistant ovarian, primary peritoneal or fallopian tube cancers that express CDH6 and were previously treated with bevacizumab.[2]
References
- ↑ "Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models". Molecular Cancer Therapeutics 23 (3): 257–271. 2024. doi:10.1158/1535-7163.MCT-23-0287. PMID 38205802.
- ↑ "Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab". https://daiichisankyo.us/documents/36782/0/US_R-DXd_FDA_BTD_Press_Release_2025-9-15.pdf/bdf3e624-79a5-ca9c-d30c-f6ee52bf60a9?t=1757858907912.
 |  |
